Cyclooxygenase-2 expression Is an independent predictor of poor prognosis in colon cancer

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8221-8227

  Ogino, Shuji ^a,b,c   Kirkner, Gregory J ^b   Nosho, Katsuhiko ^a   Irahara, Natsumi ^a   Kure, Shoko ^a   Shima, Kaori ^a   Hazra, Aditi ^b,c   Chan, Andrew T ^b,d   Dehari, Reiko ^e   Giovannucci, Edward L ^b,c   Fuchs, Charles S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLOOXYGENASE 2; K RAS PROTEIN; PROTEIN P53; PTGS2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; COLON TUMOR; ENZYMOLOGY; MIDDLE AGED; MORTALITY;

AGED; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149340659     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1841     Document Type: Article

References (50)

1. Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006;9:6-8.
2. Brown JR, Du Bois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-55.
3. Soumaoro LT,UetakeH,Higuchi T,Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-71.
4. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-41.
5. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
6. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
7. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13.
8. Tomozawa S,Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-8.
9. Gustafsson A, Hansson E, Kressner U, et al. EP1-4 subtype, COX and PPARγ receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 2007;121:232-40.
10. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-7.
11. Liang JT, Huang KC, JengYM, Lee PH, Lai HS, Hsu HC. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg 2004;91:355-61.
12. Fux R, Schwab M,Thon KP, Gleiter CH, FritzP. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11:4754-60.
13. YamacD,CelenkogluG,Coskun U, et al.Prognostic importance of COX-2 expression in patients with co-lorectal cancer. Pathol Res Pract 2005;201:497-502.
14. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002;31:147-54.
15. Wu AW,Gu J,Ji JF, Li ZF,XuGW. Role of COX-2in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003;9:1990-4.
16. Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 2008;97:51 -6.
17. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274:10911 -5.
18. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8:458-64.
19. Karnes WE, Jr., Shattuck-Brandt R, Burgart LJ, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998;58:5473-7.
20. Sinicrope FA, Lemoine M, Xi L, et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999;117:350-8.
21. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
22. Swamy MV, Herzog CR, Rao CV. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003; 63:5239-42.
23. Benoit V, de Moraes E, Dar NA, et al. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-κB. Oncogene 2006;25:5708-18.
24. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5:388-96.
25. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131 -42.
26. Baas IO, Mulder JW, Offerhaus GJ,Vogelstein B, Hamilton SR. An evaluation of six antibodies for immu-nohistochemistry of mutantp53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
27. Curtin K, Slattery ML, Holubkov R, Edwards S, Holden JA, Samowitz WS. p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol 2004;12:380-6.
28. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 2006;208:1 -6.
29. Knosel T, Yu Y, Stein U, et al. Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas. Dis Colon Rectum 2004;47:70-7.
30. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005;7:413-21.
31. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-8.
32. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007;9:305-14.
33. OginoS, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-17.
34. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
35. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38:787-93.
36. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
37. Shen L, Catalano PJ, Benson AB III, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007;13:6093-8.
38. WardRL,CheongK,KuSL,MeagherA,O'Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003;21:3729-36.
39. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009: in press (published online on 2 Oct 2008; doi.10.1136/gut.2008.155473) .
40. 2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 2005;310:1504-10.
41. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6.
42. de Heer P, Gosens MJ, de Bruin EC, et al. Cycloox-ygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res 2007;13:2955-60.
43. + tumor-infiltrating lymphocytes. Clin Cancer Res 2008; 14:3792-7.
44. Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007;13:1736-41.
45. Ginty F, Adak S, Can A, et al. The relative distribution of membranous and cytoplasmic Met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 2008;14:3814-22.
46. Rosen LS, Bilchik AJ, Beart RW, Jr., et al. New approaches to assessing and treating early-stage colon and rectal cancer:summary statement from 2007 Santa Monica Conference. Clin Cancer Res 2007;13:6853-6s.
47. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007;13:1472-9.
48. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008;14:1413-7.
49. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-47.
50. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 2000;60:4044-8.